Adenosine A2A and dopamine D2 heteromeric receptor complexes and their function

Journal of Molecular Neuroscience

Volumn 26, Issue 2-3, 2005, Pages 209-219

  Fuxe, Kjell ^a   Ferré, Sergi ^d   Canals, Meritxell ^a   Torvinen, Maria ^a   Terasmaa, Anton ^a   Marcellino, Daniel ^b   Goldberg, Steven R ^d   Staines, William ^c   Jacobsen, Kirsten X ^c   Lluis, Carmen ^b   Woods, Amina S ^d   Agnati, Luigi F ^e   Franco, Rafael ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF BARCELONA   (Spain)

^c UNIVERSITY OF OTTAWA   (Canada)

^d NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^e UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Adenosine A2A receptors; Dopamine D2 receptors; Heteromers; Parkinson's disease; Schizophrenia

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR AGONIST; ADENOSINE A2A RECEPTOR ANTAGONIST; CHIMERIC PROTEIN; DIMER; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; EPITOPE; NEUROLEPTIC AGENT; RECOMBINANT PROTEIN;

BRAIN NERVE CELL; CARBOXY TERMINAL SEQUENCE; CELL LINE; CELL MEMBRANE; CELL SURFACE; COMPLEX FORMATION; COMPUTER MODEL; CONFERENCE PAPER; CORPUS STRIATUM; MOLECULAR INTERACTION; MOLECULAR RECOGNITION; PARKINSON DISEASE; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SCHIZOPHRENIA; STOICHIOMETRY; ANIMAL; BRAIN; CHEMISTRY; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMAN; MACROMOLECULE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMANS; MACROMOLECULAR SUBSTANCES; RECEPTOR, ADENOSINE A2A; RECEPTORS, DOPAMINE D2; RECOMBINANT PROTEINS; SCHIZOPHRENIA;

EID: 25844477182     PISSN: 08958696     EISSN: None     Source Type: Journal    
DOI: 10.1385/JMN:26:2-3:209     Document Type: Conference Paper

References (57)

1. Agnati L. F., Ferré S., Lluis C., Franco R., and Fuxe K. (2003) Molecular mechanisms and therapeutical implications of intramembrane receptor/receptor interactions among heptahelical receptors with examples from the striatopallidal GABA neurons. Pharmacol. Rev. 55, 509-550.
2. Agnati L. F., Fuxe K., Zini I., Lenzi P., and Hökfelt T. (1980) Aspects on receptor regulation and isoreceptor identification. Med. Biol. 58, 182-187.
3. Andersen M. B., Fuxe K., Werge T., and Gerlach J. (2002) The adenosine A2A receptor agonist CGS 21680 exhibits antipsychotic-like activity in Cebus apella monkeys. Behav. Pharmacol. 13, 639-644.
4. Bara-Jimenez W., Sherzai A., Dimitrova T., Favit A., Bibbiani F., Gillespie M., et al. (2003) Adenosine A(2A) receptor antagonist treatment of Parkinson's disease. Neurology 61, 293-296.
5. Bofill-Cardona E., Kudlacek O., Yang Q., Ahorn H., Freissmuth M., and Nanoff C. (2000) Binding of calmodulin to the D2-dopamine receptor reduces receptor signaling by arresting the G protein activation switch. J. Biol. Chem. 275, 32672-32680.
6. Canals M., Burgueno J., Marcellino D., Cabello N., Canela E. I., Mallol J., et al. (2004) Homodimerization of adenosine A2A receptors. Qualitative and quantitative assessment by fluorescence and bioluminescence transfer. J. Neurochem. 88, 726-734.
7. 2A-dopamine D2 receptor-receptor heteromerization. Qualitative and quantitative assessment of fluorescence and bioluminescence energy transfer. J. Biol. Chem. 278, 46741-46749.
8. Ciruela F., Burgueno J., Casado V., Canals M., Marcelino D., Goldberg S. R., et al. (2004) Combining mass spectrometry and pull-down techniques for the study of receptor heteromerization. Direct epitope-epitope electrostatic interactions between adenosine A2A and dopamine D2 receptors. Anal. Chem. 76, 5354-5363.
9. 2 receptors in stably cotransfected fibroblast cells. Eur. J. Pharmacol. 316, 325-331.
10. Díaz-Cabiale Z., Hurd Y., Guidolin D., Finnman U. B., Zoli M., Agnati L. F., et al. (2001) Adenosine A2A agonist CGS 21680 decreases the affinity of dopamine D2 receptors for dopamine in human striatum. NeuroReport 12, 1831-1834.
11. Ferré S. (1997) Adenosine-dopamine interactions in the ventral striatum. Implications for the treatment of schizophrenia. Psychopharmacology 133, 107-120.
12. Ferré S. and Fuxe K. (1992) Dopamine denervation leads to an increase in the membrane interaction between adenosine A2 and dopamine D2 receptors in the neostriatum. Brain Res. 594, 124-130.
13. Ferré S., Ciruela F., Canals M., Marcellino D., Burgueno J., Casado V., et al. (2004) Adenosine A2A-dopamine D2 receptor-receptor heteromers. Targets for neuro-psychiatric disorders. Parkinsonism Relat. Disord. 10, 265-271.
14. 2 receptor interactions in the striatum. Implications for drug therapy in neuropsychiatric disorders and drug abuse. Curr. Med. Chem. CNS Agents 33, 1-26.
15. Ferré S., Fredholm B. B., Morelli M., Popoli P., and Fuxe K. (1997) Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci. 20, 482-487.
16. Ferré S., Fuxe K., von Euler G., Johansson B., and Fredholm B. B. (1992) Adenosine-dopamine interactions in the brain. Neuroscience 51, 501-512.
17. 2A and glutamate mGlu5 receptors: Implications for striatal neuronal function. Proc. Natl. Acad. Sci. U. S. A. 99, 11940-11945.
18. 2 receptors in the ventral striopallidal system. Implications for the treatment of schizophrenia. Neuroscience 63, 765-773.
19. Ferré S., Popoli P., Giménez-Llort L., Rimondini R., Müller C. E., Strömberg I., et al. (2001) Adenosine/dopamine interaction: implications for the treatment of Parkinson's disease. Parkinsonism Relat. Disord. 7, 235-241.
20. Ferré S., von Euler G., Johansson B., Fredholm B. B., and Fuxe K. (1991) Stimulation of high affinity adenosine A-2 receptors decreases the affinity of dopamine D-2 receptors in rat striatal membranes. Proc. Natl. Acad. Sci. U. S. A. 88, 7238-7241.
21. Fink J. S., Weaver D. R., Rivkees S. A., Peterfreund R. A., Pollack A., Adler E. M., and Reppert S. M. (1992) Molecular cloning of the rat A2 adenosine receptor: selective co-expression with D2 dopamine receptors in rat striatum. Mol. Brain Res. 14, 186-195.
22. 3H] spiroperidol binding in rat striatum: evidence for increased affinity and reduction in the number of binding sites. Acta Physiol. Scand. 113, 567-569.
23. 2A receptor signaling. Relevance for striatal function and Parkinson's disease. Neurology 61(Suppl. 6), S19-S23.
24. Fuxe K. and Agnati L. F. (1985) Receptor-receptor interactions in the central nervous system. A new integrative mechanism in synapses. Med. Res. Rev. 5, 441-482.
25. Fuxe K. and Agnati L. F. (1987) Receptor-Receptor Interactions. A New Intramembrane Integrative Mechanism. Macmillan Press, London, UK.
26. Fuxe K. and Ungerstedt U. (1974) Action of caffeine and theophyllamine on supersensitive dopamine receptors: considerable enhancement of receptor response to treatment with dopa and dopamine receptor agonists. Med. Biol. 52,48-54.
27. Fuxe K., Ferré S., Zoli M., and Agnati L. F. (1998) Integrated events in central dopamine transmission as analyzed at multiple levels. Evidence for intra membrane adenosine A2A/dopamine D2 and adenosine A1/dopamine D1 receptor interactions in the basal ganglia. Brain Res. Rev. 26, 258-273.
28. Fuxe K., Strömberg I., Popoli P., Rimondini-Giorgini R., Torvinen M., Ogren S. O., et al. (2001) Adenosine receptors and Parkinson's disease. Relevance of antagonistic adenosine and dopamine receptor interactions in the striatum. Adv. Neurol. 86, 345-353.
29. Gouldson P. R., Higgs C., Smith R. E., Dean M. K., Gkoutos G. V., and Reynolds C. A. (2000) Dimerization and domain swapping in G-protein-coupled receptors: a computational study. Neuropsychopharmacology 23, 60-77.
30. Guo W., Shi L., and Javitch J. A. (2003) The fourth transmembrane segment forms the interface of the dopamine D2 receptor homodimer. J. Biol. Chem. 278, 4385-4388.
31. Hauser R. A., Hubble J. P., and Truong D. D. (2003) Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD. Neurology 61, 297-303.
32. Hettinger B. D., Lee A., Linden J., and Rosin D. L. (2001) Ultrastructural localization of adenosine A2A receptors suggests multiple cellular sites for modulation of GABAergic neurons in rat striatum. J. Comp. Neurol. 431, 331-346.
33. Hillefors M., Hedlund P. B., and von Euler G. (1999) Effects of adenosine A(2A) receptor stimulation in vivo on dopamine D3 receptor agonist binding in the rat brain. Biochem. Pharmacol. 58, 1961-1964.
34. Hillion J., Canals M., Torvinen M., Casado V., Scott R., Terasmaa A., et al. (2002) Coaggregation, cointernalization and codesensitization of adenosine A2A receptors and dopamine D2 receptors. J. Biol. Chem. 277, 18091-18097.
35. Kamiya T., Saitoh O., Yoshioka K., and Nakata H. (2003) Oligomerization of adenosine A2A and dopamine D2 receptors in living cells. Biochem. Biophys. Res. Commun. 306, 544-549.
36. Kudlacek O., Just H., Korkhov V. M., Vartian N., Klinger M., Pankevych H., et al. (2003) The human D2 dopamine receptor synergizes with the A2A adenosine receptor to stimulate adenylyl cyclase in PC12 cells. Neuropsychopharmacology 28, 1317-1327.
37. Kull B., Ferré S., Arslan G., Svenningsson P., Fuxe K., Owman C., and Fredholm B. B. (1999) Reciprocal interactions between adenosine A2A and dopamine D2 receptors in Chinese hamster ovary cells co-transfected with the two receptors. Biochem. Pharmacol. 58, 1035-1045.
38. Lee K. W., Hong J. H., Choi I. Y., Che Y., Lee J. K., Yang S. D., et al. (2002) Impaired D2 dopamine receptor function in mice lacking type 5 adenylyl cyclase. J. Neurosci. 22, 7931-7940.
39. Lee S. P., Xie Z., Varghese G., Nguyen T., O'Dowd B. F., and George S. (2000) Oligomerization of dopamine and serotonin receptors. Neuropsychopharmacology 23, S32-S40.
40. Mellado M., Vila-Coro A. J., Martinez C., and Rodriguez-Frade J. M. (2002) Receptor dimerization: a key step in chemokine signaling. Cell. Mol. Biol. 47, 575-582.
41. Nimchinsky E. .A., Hof P. R., Janssen W. G., Morrison J. H., and Schmauss C. (1997) Expression of dopamine D3 receptor dimers and tetramers in brain an in transfected cells. J. Biol. Chem. 272, 29229-29237.
42. Patel R. C., Kumar U., Lamb D. C., Eid J. S., Rocheville M., Grant M., et al. (2002) Ligand binding to somatostatin receptors induces receptor-specific oligomer formation in live cells. Proc. Natl. Acad. Sci. U. S. A. 99, 3294-3299.
43. Rimondini R., Ferré S., Ogren S. O., and Fuxe K. (1997) Adenosine A2A agonists: a potential new type of atypical antipsychotic. Neuropsychopharmacology 17, 82-91.
44. Rocheville M., Lange D. C., Kumar U., Patel S. C., Patel R. C., and Patel Y. C. (2000) Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 288, 154-157.
45. Salim H., Ferré S., Dalal A., Peterfreund R. A., Fuxe K., Vincent J.- D., and Lledo P. M. (2000) Activation of adenosine A1 and A2A receptors modulates dopamine D2 receptor-induced responses in stably transfected humanneuroblastoma cells. J. Neurochem. 74, 432-439.
46. 3 dopamine receptor heterodimers exhibit unique functional properties. J. Biol. Chem. 276, 30308-30314.
47. 2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: an in situ hybridization histochemistry study. J. Neurochem. 57, 1062-1067.
48. Schwartz J. C., Diaz J., Pilon C., and Sokoloff P. (2000) Possible implications of the dopamine D(3) receptor in schizophrenia and in antipsychotic drug actions. Brain Res. Brain. Res. Rev. 31, 277-287.
49. Svenningsson P., Lindskog M., Ledent C., Parmentier M., Greengard P., Fredholm B. B., and Fisone G. (2000) Regulation of the phosphorylation of the dopamine-and cAMP-regulated phosphoprotein of 32 kDa in vivo by dopamine D1, dopamine D2, and adenosine A2A receptors. Proc. Natl. Acad. Sci. U. S. A. 97, 1856-1860.
50. Tanganelli S., Sandager Nielsen K., Ferraro L., Antonelli T., Kehr J., Franco R., et al. (2004) Striatal plasticity at the network level. Focus on adenosine A2A and D2 interactions in models of Parkinson's disease. Parkinsonism Relat. Disord. 10, 273-280.
51. Terrillon S. and Bouvier M. (2004) Roles of G-protein-coupled receptor dimerization. EMBO Rep. 5, 30-34.
52. 2A receptor. J. Mol. Neurosci. 24, 273-280.
53. 2 receptors. J. Mol. Neurosci., 25, 191-200.
54. 3 heteromeric complexes. Mol. Pharmacol. 67, 400-407.
55. Vortherms T. A. and Watts V. J. (2004) Sensitization of neuronal A2A adenosine receptors after persistent D2 dopamine receptor activation. J. Pharmacol. Exp. Ther. 308, 221-227.
56. Yao L., Arolfo M. P., Dohrman D. P., Jiang Z., Fan P., Fuchs S., et al. (2002) βγ Dimers mediate synergy of dopamine D2 and adenosine A2 receptor-stimulated PKA signaling and regulate ethanol consumption. Cell 109, 733-743.
57. Zoli M., Agnati L. F., Hedlund P. B., Li X. M., Ferré S., and Fuxe K. (1993) Receptor-receptor interactions as an integrative mechanism in nerve cells. Mol. Neurobiol. 7, 293-334.